Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Grifols
33 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
New CDMO Facility
Leveraging a State-of-the-Art CDMO Facility to Advance Healthcare
PAO-02-23-PATV-04
Parenteral Drug Products
Innovating to Optimize Quality in Injectable Drugs
PAO-11-022-CL-16
Alzheimer's Vaccine
Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's
PR-M03-22-06
Parenteral Manufacturing
Staying Ahead of Trends in Small-Volume Parenteral Manufacturing
PAO-01-22-R250-08
Recombinant Proteins
Meeting the Renewed Demand for Microbial Protein Production
PAO-01-22-R250-07
Parenteral Drugs
A CDMO Dedicated to Supporting Small-Volume, Small-Molecule Parenteral Projects
PAO-12-21-CL-02
Hyperimmunes
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
PR-M04-21-018
Acquisition
Grifols Reinforces its Innovation Strategy After Completing the Acquisition of GigaGen to Boost a Novel Method to Generate a Wide Range of Immunoglobulins
PR-M11-20-045
Parenterals
Trends Shaping the Dynamic Market for Parenterals
PAP-Q3-20-CL-018
Continuous Improvement
The Critical Role of Continuous Improvement in Parenteral Drug Manufacturing
PAP-Q1-20-CL-010
M&A
Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.
PR-M02-20-NI-031
Orphan Drugs
Customer Engagement and Information Sharing are Essential for Success in Orphan Drug Outsourcing
PAP-Q3-19-CL-013
FDA Approval
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
PR-M07-19-NI-018
Parenteral Manufacturing
Catering to a Growing Demand for Small-Volume Parenteral Manufacturing
PAO-M04-19-CL-001
Parenteral Solutions
Supporting Small and Emerging Pharma through Collaboration and Specialized Expertise
PAP-Q2-2019-CL-017
Form-Fill-Seal
Investing in Form-Fill-Seal Technology
PAP-Q1-2019-CL-011
Facility Opening
Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR
PR-M03-19-NI-082
FDA Approval
Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
PR-M02-19-NI-017
Quality
Continuous Quality is Essential in Parenteral Manufacturing
PAO-M12-18-CL-003
FDA Approval
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
PR-M10-18-NI-047
Terminal Sterilization
Terminal Sterilization for Parenteral Drugs: Finding the Right CDMO Partner
PAP-Q3-18-CL-015
FDA Approval
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
PR-M08-18-NI-123
Parenterals
A Risk Analysis Approach to Producing Environmentally Sensitive Parenterals
PA0-M06-18-CL-007
FDA Approval
Grifols Expands its NAT Solutions Portfolio with New FDA Approvals for Two Assays
PR-M06-18-NI-064
1
2
»
